Roche has accomplished with its product candidates Ipatasertib in combination with a hormone, and cortisone therapy in the treatment of prostate cancer, the goals only partially.
Roche announced on Friday, was reduced in the Phase III study IPATential150 at a specific group of patients, the risk of deterioration is clear.
These patients suffered from a metastatic castration-resistant prostate cancer, which showed a loss of the tumor suppressor gene (PTEN loss), and. On the other hand, but the second objective to achieve in all of the study participants, a radio graphic progression-free Survival (rPFS), is not achieved.
You will continue the study until the next scheduled analysis and data to inform the health authorities, it is said in the message. According to data, prostate cancer is one of the most common causes of death in men, and patients with metastatic, castration-resistant prostate cancer are often difficult to treat.
The Roche share price in early Swiss trading to 1.62 percent to 342,90 francs.